Novavax Shares Outstanding History (NVAX)
Novavax reported 162.6M shares outstanding at the end of fiscal 2025.
View full Novavax company overviewNovavax annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 162.6M | 2.2M | +1.34% |
| 2024 | 2024-12-31 | 160.4M | 20.9M | +14.99% |
| 2023 | 2023-12-31 | 139.5M | 53.5M | +62.14% |
| 2022 | 2022-12-31 | 86.0M | 10.2M | +13.45% |
| 2021 | 2021-12-31 | 75.8M | 4.9M | +6.89% |
| 2020 | 2020-12-31 | 71.0M | 69.3M | +4286.30% |
| 2019 | 2019-12-31 | 1.6M | 1.6M | +3266.11% |
| 2018 | 2018-12-31 | 48,056.025 | −16.1M | −99.70% |
| 2017 | 2017-12-31 | 16.2M | 2.6M | +19.16% |
| 2016 | 2016-12-31 | 13.6M | 63,736.75 | +0.47% |
| 2015 | 2015-12-31 | 13.5M | 1.6M | +13.04% |
| 2014 | 2014-12-31 | 11.9M | 1.5M | +14.46% |
| 2013 | 2013-12-31 | 10.4M | 3.0M | +41.04% |
| 2012 | 2012-12-31 | 7.4M | 1.5M | +26.42% |
| 2011 | 2011-12-31 | 5.9M | 299,442.65 | +5.39% |
| 2010 | 2010-12-31 | 5.6M | — | — |
Novavax quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 164.8M | 2.7M | +1.64% |
| Q1 2026 | 2026-03-31 | 164.4M | 2.5M | +1.52% |
| Q4 2025 | 2025-12-31 | 162.6M | 2.2M | +1.34% |
| Q3 2025 | 2025-09-30 | 162.5M | 2.3M | +1.45% |
| Q2 2025 | 2025-06-30 | 162.2M | 2.3M | +1.42% |
| Q1 2025 | 2025-03-31 | 162.0M | 21.6M | +15.38% |
| Q4 2024 | 2024-12-31 | 160.4M | 20.9M | +14.99% |
| Q3 2024 | 2024-09-30 | 160.1M | 41.4M | +34.88% |
| Q2 2024 | 2024-06-30 | 159.9M | 65.6M | +69.54% |
| Q1 2024 | 2024-03-31 | 140.4M | 54.1M | +62.67% |
| Q4 2023 | 2023-12-31 | 139.5M | 53.5M | +62.14% |
| Q3 2023 | 2023-09-30 | 118.7M | 40.3M | +51.29% |
| Q2 2023 | 2023-06-30 | 94.3M | 16.1M | +20.65% |
| Q1 2023 | 2023-03-31 | 86.3M | 8.2M | +10.46% |
| Q4 2022 | 2022-12-31 | 86.0M | 10.2M | +13.45% |
| Q3 2022 | 2022-09-30 | 78.5M | 74.7M | +1981.18% |
| Q2 2022 | 2022-06-30 | 78.2M | 74.5M | +2005.56% |
| Q1 2022 | 2022-03-31 | 78.1M | 74.4M | +2009.68% |
| Q4 2021 | 2021-12-31 | 75.8M | 72.3M | +2037.76% |
| Q3 2021 | 2021-09-30 | 3.8M | 3.6M | +2296.91% |
| Q2 2021 | 2021-06-30 | 3.7M | 3.6M | +2325.97% |
| Q1 2021 | 2021-03-31 | 3.7M | 3.6M | +2650.41% |
| Q4 2020 | 2020-12-31 | 3.5M | 3.5M | +4286.30% |
| Q3 2020 | 2020-09-30 | 157,318.713 | 93,497.108 | +146.50% |
| Q2 2020 | 2020-06-30 | 153,028.058 | 94,346.623 | +160.78% |
| Q1 2020 | 2020-03-31 | 134,637.283 | 75,955.848 | +129.44% |
| Q4 2019 | 2019-12-31 | 80,881.04 | −1.1M | −93.11% |
| Q3 2019 | 2019-09-30 | 63,821.605 | −23.4M | −99.73% |
| Q2 2019 | 2019-06-30 | 58,681.435 | −19.2M | −99.69% |
| As of May 10, 2019 | 2019-05-10 | 58,681.435 | −19.1M | −99.69% |
| As of May 9, 2019 | 2019-05-09 | 1.2M | −17.9M | −93.85% |
| Q1 2019 | 2019-03-31 | 23.5M | 6.1M | +35.39% |
| Q4 2018 | 2018-12-31 | 19.2M | 3.1M | +18.94% |
| Q3 2018 | 2018-09-30 | 19.1M | 3.6M | +23.39% |
| Q2 2018 | 2018-06-30 | 19.1M | 4.6M | +31.65% |
| Q1 2018 | 2018-03-31 | 17.3M | 3.2M | +22.69% |
| Q4 2017 | 2017-12-31 | 16.2M | 2.6M | +19.16% |
| Q3 2017 | 2017-09-30 | 15.5M | 1.9M | +14.36% |
| Q2 2017 | 2017-06-30 | 14.5M | 951,974.1 | +7.03% |
| Q1 2017 | 2017-03-31 | 14.1M | 592,143.65 | +4.37% |
| Q4 2016 | 2016-12-31 | 13.6M | 63,736.75 | +0.47% |
| Q3 2016 | 2016-09-30 | 13.6M | 70,969.8 | +0.53% |
| Q2 2016 | 2016-06-30 | 13.5M | 111,976.05 | +0.83% |
| Q1 2016 | 2016-03-31 | 13.5M | 142,224.85 | +1.06% |
| Q4 2015 | 2015-12-31 | 13.5M | 1.6M | +13.04% |
| Q3 2015 | 2015-09-30 | 13.5M | 1.6M | +13.15% |
| Q2 2015 | 2015-06-30 | 13.4M | 1.5M | +12.82% |
| Q1 2015 | 2015-03-31 | 13.4M | 2.9M | +28.04% |
| Q4 2014 | 2014-12-31 | 11.9M | 1.5M | +14.46% |
| Q3 2014 | 2014-09-30 | 11.9M | 1.5M | +14.36% |
| Q2 2014 | 2014-06-30 | 11.9M | 4.3M | +55.93% |
| Q1 2014 | 2014-03-31 | 10.5M | 2.9M | +38.36% |
| Q4 2013 | 2013-12-31 | 10.4M | 3.0M | +41.04% |
| Q3 2013 | 2013-09-30 | 10.4M | 3.6M | +53.83% |
| Q2 2013 | 2013-06-30 | 7.6M | 1.0M | +15.56% |
| Q1 2013 | 2013-03-31 | 7.6M | 1.5M | +23.86% |
| Q4 2012 | 2012-12-31 | 7.4M | 1.5M | +26.42% |
| Q3 2012 | 2012-09-30 | 6.8M | 1.0M | +17.94% |
| Q2 2012 | 2012-06-30 | 6.6M | 874,126.9 | +15.25% |
| Q1 2012 | 2012-03-31 | 6.1M | 553,833.9 | +9.98% |
| Q4 2011 | 2011-12-31 | 5.9M | — | — |
| Q3 2011 | 2011-09-30 | 5.7M | — | — |
| Q2 2011 | 2011-06-30 | 5.7M | — | — |
| Q4 2010 | 2010-12-31 | 5.6M | — | — |
Novavax shares outstanding trends
Over the last five reported fiscal years, Novavax's shares outstanding moved from 71.0M to 162.6M, a change of 91.6M. The latest reported quarter, Q2 2026, shows 164.8M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Novavax filings at SEC.gov ↗